Literature DB >> 1369413

Multiple drug-resistance in variant of a human non-small cell lung carcinoma cell line, DLKP-A.

M Clynes1, A Redmond, E Moran, U Gilvarry.   

Abstract

A 300-fold adriamycin resistant variant (DLKP-A) of the human lung squamous cell carcinoma line DLKP was established by stepwise selection in increasing concentrations of adriamycin. Different levels of cross-resistance were observed towards VP-16, VM-26, colchicine, vincristine and, somewhat unexpectedly, cis-platin. Resistance was stable for at least 3 months in culture in the absence of drug. P-glycoprotein overexpression was detected by immunofluorescence and Western Blotting, and a direct causal role for P-glycoprotein overexpression in the resistant phenotype was established by transfection with an mdr1 specific antisense oligonucleotide. A modified cryopreservation procedure was necessary for the resistant variant line. The resistant population displays clonal heterogeneity with respect to resistance level. A higher frequency of double minute chromosomes was observed in DLKP-A when compared with the parental cell line.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1369413     DOI: 10.1007/bf00376102

Source DB:  PubMed          Journal:  Cytotechnology        ISSN: 0920-9069            Impact factor:   2.058


  30 in total

1.  Volume-regulated chloride channels associated with the human multidrug-resistance P-glycoprotein.

Authors:  M A Valverde; M Díaz; F V Sepúlveda; D R Gill; S C Hyde; C F Higgins
Journal:  Nature       Date:  1992-02-27       Impact factor: 49.962

2.  Distribution of multi-drug resistance-associated P-glycoprotein in normal and neoplastic human tissues. Analysis with 3 monoclonal antibodies recognizing different epitopes of the P-glycoprotein molecule.

Authors:  P van der Valk; C K van Kalken; H Ketelaars; H J Broxterman; G Scheffer; C M Kuiper; T Tsuruo; J Lankelma; C J Meijer; H M Pinedo
Journal:  Ann Oncol       Date:  1990       Impact factor: 32.976

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

4.  Fading of immunofluorescence during microscopy: a study of the phenomenon and its remedy.

Authors:  G D Johnson; R S Davidson; K C McNamee; G Russell; D Goodwin; E J Holborow
Journal:  J Immunol Methods       Date:  1982-12-17       Impact factor: 2.303

5.  Mechanisms of resistance to etoposide and teniposide in acquired resistant human colon and lung carcinoma cell lines.

Authors:  B H Long; L Wang; A Lorico; R C Wang; M G Brattain; A M Casazza
Journal:  Cancer Res       Date:  1991-10-01       Impact factor: 12.701

6.  Measurement of protein using bicinchoninic acid.

Authors:  P K Smith; R I Krohn; G T Hermanson; A K Mallia; F H Gartner; M D Provenzano; E K Fujimoto; N M Goeke; B J Olson; D C Klenk
Journal:  Anal Biochem       Date:  1985-10       Impact factor: 3.365

7.  Energy-dependent processes involved in reduced drug accumulation in multidrug-resistant human lung cancer cell lines without P-glycoprotein expression.

Authors:  C H Versantvoort; H J Broxterman; H M Pinedo; E G de Vries; N Feller; C M Kuiper; J Lankelma
Journal:  Cancer Res       Date:  1992-01-01       Impact factor: 12.701

8.  MDR1 gene expression in lung cancer.

Authors:  S L Lai; L J Goldstein; M M Gottesman; I Pastan; C M Tsai; B E Johnson; J L Mulshine; D C Ihde; K Kayser; A F Gazdar
Journal:  J Natl Cancer Inst       Date:  1989-08-02       Impact factor: 13.506

9.  Reduced DNA topoisomerase II activity and drug-induced DNA cleavage activity in an adriamycin-resistant human small cell lung carcinoma cell line.

Authors:  S de Jong; J G Zijlstra; E G de Vries; N H Mulder
Journal:  Cancer Res       Date:  1990-01-15       Impact factor: 12.701

10.  Alterations in glutathione and glutathione-related enzymes in a multidrug-resistant small cell lung cancer cell line.

Authors:  S P Cole; H F Downes; S E Mirski; D J Clements
Journal:  Mol Pharmacol       Date:  1990-02       Impact factor: 4.436

View more
  15 in total

1.  A new mdr-1 encoded P-170 specific monoclonal antibody: (6/1C) on paraffin wax embedded tissue without pretreatment of sections.

Authors:  E Moran; A Larkin; G Doherty; P Kelehan; S Kennedy; M Clynes
Journal:  J Clin Pathol       Date:  1997-06       Impact factor: 3.411

Review 2.  Cellular models for multiple drug resistance in cancer.

Authors:  M Clynes
Journal:  In Vitro Cell Dev Biol       Date:  1993-03

3.  mdr1 ribozyme mediated reversal of the multi-drug resistant phenotype in human lung cell lines.

Authors:  C Daly; S Coyle; S McBride; L O'Driscoll; N Daly; K Scanlon; M Clynes
Journal:  Cytotechnology       Date:  1996       Impact factor: 2.058

4.  Absence of correlation between chemo- and radioresistance in a range of human tumour cell lines.

Authors:  M Heenan; K Kavanagh; A Redmond; M Maher; E Dolan; P O'Neill; M Moriarty; M Clynes
Journal:  Cytotechnology       Date:  1996       Impact factor: 2.058

5.  Modulation of P-gp expression by lapatinib.

Authors:  Gráinne Dunne; Laura Breen; Denis M Collins; Sandra Roche; Martin Clynes; Robert O'Connor
Journal:  Invest New Drugs       Date:  2010-07-06       Impact factor: 3.850

6.  The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias.

Authors:  Robert O'Connor; Melissa G Ooi; Justine Meiller; Jana Jakubikova; Steffen Klippel; Jake Delmore; Paul Richardson; Kenneth Anderson; Martin Clynes; Constantine S Mitsiades; Peter O'Gorman
Journal:  Cancer Chemother Pharmacol       Date:  2013-04-16       Impact factor: 3.333

7.  Tyrosine kinase inhibitors potentiate the cytotoxicity of MDR-substrate anticancer agents independent of growth factor receptor status in lung cancer cell lines.

Authors:  D M Collins; J Crown; N O'Donovan; A Devery; F O'Sullivan; L O'Driscoll; M Clynes; R O'Connor
Journal:  Invest New Drugs       Date:  2009-06-05       Impact factor: 3.850

Review 8.  Human cell lines as models for multidrug resistance in solid tumours.

Authors:  M Clynes; M Heenan; K Hall
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

Review 9.  Differing patterns of cross-resistance resulting from exposures to specific antitumour drugs or to radiation in vitro.

Authors:  B T Hill
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

10.  Use of ribozymes and antisense oligodeoxynucleotides to investigate mechanisms of drug resistance.

Authors:  D Byrne; C Daly; R Nicamhlaoibh; A Howlett; K Scanlon; M Clynes
Journal:  Cytotechnology       Date:  1998-09       Impact factor: 2.058

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.